Samsung Biologics announced an all-cash bid for Swiss drugmaker PolyPeptide
Question
Samsung Biologics announced an all-cash bid for Swiss drugmaker PolyPeptide
Direct answer
PolyPeptide shares and the Swiss pharma M&A complex are directly affected.
- Original publisher
- Market Ontology
- Evidence through
- 2026-07-20
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Samsung Biologics announced an all-cash bid for Swiss drugmaker PolyPeptide”, revision 1, evidence through 2026-07-20. https://marketontology.com/market-events/2026-07-20/samsung-biologics-announced-an-all-cash-bid-for-swiss-drugmaker-polypeptide-9b3124
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
Related
- 2026-07-20Samsung Biologics announced an all-cash bid for Swiss drugmaker PolyPeptidePOLYPEPTIDE
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.